AR060506A1 - Compuestos organicos - Google Patents

Compuestos organicos

Info

Publication number
AR060506A1
AR060506A1 ARP070101533A ARP070101533A AR060506A1 AR 060506 A1 AR060506 A1 AR 060506A1 AR P070101533 A ARP070101533 A AR P070101533A AR P070101533 A ARP070101533 A AR P070101533A AR 060506 A1 AR060506 A1 AR 060506A1
Authority
AR
Argentina
Prior art keywords
carbon atoms
alkyl
formula
halogen
compound
Prior art date
Application number
ARP070101533A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0607532A external-priority patent/GB0607532D0/en
Priority claimed from GB0610244A external-priority patent/GB0610244D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR060506A1 publication Critical patent/AR060506A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/12Nitrogen atoms not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Reivindicacion 1: Un proceso para la preparacion de compuestos de la Formula (1) o un solvato o hidrato de los mismos, en donde: R es fenilo que está insustituido o que está sustituido por 1, 2, o 3 sustituyentes seleccionados a partir del grupo que consiste en halogeno, alquilo de 1 a 7 átomos de carbono, trifluoro-metilo, hidroxilo, y alcoxilo de 1 a 7 átomos de carbono; R1 es hidrogeno o alquilo de 1 a 7 átomos de carbono; R2 es hidrogeno, alquilo de 1 a 7 átomos de carbono, o fenilo que está insustituido o que está sustituido por 1, 2, o 3 sustituyentes seleccionados a partir del grupo que consiste en halogeno, alquilo de 1 a 7 átomos de carbono, trifluoro-metilo, hidroxilo, y alcoxilo de 1 a 7 átomos de carbono; R3 es fenilo que está insustituido o que está sustituido por 1, 2, o 3 sustituyentes seleccionados a partir del grupo que consiste en halogeno, alquilo de 1 a 7 átomos de carbono, trifluoro-metilo, hidroxilo, y alcoxilo de 1 a 7 átomos de carbono, o r3 es nftilo, 1H- indol-3-ilo, o 1-alquilo de 1 a 7 átomos de carbono-indol-3-ilo, y R5 eds cicloalquilo de 3 a 8 átomos de carbono, D-azacicloheptan-2-on-3-ilo o L-aza-cicloheptan-2-on-3-ilo, comprendiendo el proceso los pasos de: (a) Hacer reaccionar un compuesto de la Formula (2) en donde R1, R2, R3, y R5 son como se definen en esta reivindicacion anteriormente, y T es un grupo protector, con una base, para formar un compuesto de la Formula (3); en donde R1, R2, R3, R5 son como se definen en esta reivindicacion anteriormente; y (b) hacer reaccionar un compuesto de la Formula ll. como R1, R2, R3, y R5 son como se definen en esta reivindicacion anteriormente, con un compuesto de la Formula (4) por 1, 2, o 3 sustituyentes seleccionados a partir del grupo que consiste en halogeno, alquilon de 1 a 7 átomos de carbono, trifluorometilo, hidroxilo y alcoxilo de 1 a 7 átomos de carbono, y X es halogeno, en la presencia de una base, para formar un compuesto de la Formula 1, y c) opcionalmente, formal un solvato o hidrato deseado de los mismos.
ARP070101533A 2006-04-13 2007-04-11 Compuestos organicos AR060506A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0607532A GB0607532D0 (en) 2006-04-13 2006-04-13 Organic compounds
GB0610244A GB0610244D0 (en) 2006-05-23 2006-05-23 Organic compounds

Publications (1)

Publication Number Publication Date
AR060506A1 true AR060506A1 (es) 2008-06-25

Family

ID=38324102

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101533A AR060506A1 (es) 2006-04-13 2007-04-11 Compuestos organicos

Country Status (29)

Country Link
US (2) US8008479B2 (es)
EP (1) EP2010498B1 (es)
JP (1) JP5208917B2 (es)
KR (1) KR20080108291A (es)
AR (1) AR060506A1 (es)
AT (1) ATE486853T1 (es)
AU (1) AU2007237482B2 (es)
CA (1) CA2645362C (es)
CL (1) CL2007001040A1 (es)
CY (1) CY1111294T1 (es)
DE (1) DE602007010269D1 (es)
DK (1) DK2010498T3 (es)
EC (1) ECSP088820A (es)
GT (1) GT200800209A (es)
HK (1) HK1125640A1 (es)
HR (1) HRP20110045T1 (es)
JO (1) JO2630B1 (es)
MA (1) MA30394B1 (es)
MX (1) MX2008013117A (es)
MY (1) MY145069A (es)
NO (1) NO20084783L (es)
NZ (1) NZ571142A (es)
PE (1) PE20071223A1 (es)
PL (1) PL2010498T3 (es)
PT (1) PT2010498E (es)
RU (1) RU2433122C2 (es)
SI (1) SI2010498T1 (es)
TW (1) TW200815358A (es)
WO (1) WO2007118651A1 (es)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007004261A (es) 2004-10-12 2007-06-18 Fmc Biopolymer As Sistemas de alginato auto-gelificantes y usos de los mismos.
ES2396365T3 (es) 2005-07-29 2013-02-21 Concert Pharmaceuticals Inc. Nuevos derivados de benzo[D][1,3]-dioxol deuterados como inhibidores de la recaptación de serotonina
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
US8071596B2 (en) 2007-01-12 2011-12-06 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
US8080549B2 (en) 2007-01-12 2011-12-20 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
WO2008106125A2 (en) 2007-02-26 2008-09-04 Concert Pharmaceuticals, Inc. Deuterated derivatives of silodosin as alpha la-adrenoceptor antagonists
ES2395241T3 (es) 2007-03-07 2013-02-11 Concert Pharmaceuticals Inc. Derivados deuterados de piperazina como compuestos antianginosos
ES2559838T3 (es) 2007-03-16 2016-02-16 Concert Pharmaceuticals, Inc. Inhibidores de proteína de transferencia de ésteres de colesterol
WO2008128166A1 (en) 2007-04-13 2008-10-23 Concert Pharmaceuticals Inc. Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds
US8349817B2 (en) 2007-04-25 2013-01-08 Concert Pharmaceuticals, Inc. Analogues of cilostazol
EP2527336A1 (en) 2007-04-25 2012-11-28 Concert Pharmaceuticals Inc. Deuterated analogues of cilostazol
CA3208128A1 (en) 2007-05-01 2008-11-13 Sun Pharmaceutical Industries, Inc. Morphinan compounds
PL2522667T3 (pl) 2007-05-01 2015-01-30 Concert Pharmaceuticals Inc Związki morfinanu
US7820666B2 (en) 2007-05-08 2010-10-26 Concert Pharmaceuticals, Inc. Tetrahydrotriazolopyrazine derivatives and uses thereof
JP2010529196A (ja) 2007-06-12 2010-08-26 コンサート ファーマシューティカルズ インコーポレイテッド アザペプチド誘導体
US7687509B2 (en) 2007-07-09 2010-03-30 Concert Pharmaceuticals Inc. Pyrimidinecarboxamide derivatives
ES2425183T3 (es) 2007-08-14 2013-10-11 Concert Pharmaceuticals Inc. Derivados de oxazolidinonas sustituidas
CN101918007B (zh) 2007-08-28 2014-06-04 Fmc有限公司 延迟的自胶凝藻酸盐体系及其应用
ES2406479T3 (es) 2007-09-12 2013-06-07 Concert Pharmaceuticals Inc. Derivado deuterado de 4-oxoquinolina para el tratamiento de la infección por VIH
CA2698808A1 (en) 2007-09-13 2009-03-19 Concert Pharmaceuticals, Inc. Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof
US8410124B2 (en) 2007-10-18 2013-04-02 Concert Pharmaceuticals Inc. Deuterated etravirine
US8592487B2 (en) 2007-10-26 2013-11-26 Concert Pharmaceuticals, Inc. Deuterated darunavir
WO2009079637A1 (en) 2007-12-18 2009-06-25 Concert Pharmaceuticals, Inc. Tetrahydroisoquinoline derivatives
WO2009094210A1 (en) 2008-01-22 2009-07-30 Concert Pharmaceuticals Inc. Vandetanib derivatives
EP2242493B1 (en) 2008-01-22 2013-06-05 Concert Pharmaceuticals Inc. Derivatives of gefitinib
US20090239886A1 (en) 2008-02-29 2009-09-24 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
US8367674B2 (en) 2008-04-17 2013-02-05 Concert Pharmaceuticals, Inc. Piperazine derivatives
US8354557B2 (en) 2008-06-17 2013-01-15 Concert Pharmaceuticals, Inc. Synthesis of deuterated morpholine derivatives
ES2451542T3 (es) 2008-08-29 2014-03-27 Concert Pharmaceuticals Inc. Derivados de triazolo-piridazina sustituidos
EP2334621A1 (en) 2008-09-16 2011-06-22 Concert Pharmaceuticals, Inc. Deuterated 2-amino-3-hydroxypropanoic acid derivatives
ES2750825T3 (es) 2008-09-19 2020-03-27 Concert Pharmaceuticals Inc Compuestos de morfinano deuterados
US9045453B2 (en) 2008-11-14 2015-06-02 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
EA201101207A1 (ru) * 2009-02-24 2012-04-30 Новартис Аг Применение антагонистов рецептора nk
US8263601B2 (en) 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
DE102009001446A1 (de) 2009-03-10 2010-09-23 Evonik Rohmax Additives Gmbh Verwendung von Kammpolymeren als Antifatigue-Additive
BRPI1009199A2 (pt) 2009-03-17 2016-03-08 Concert Pharmaceuticals Inc compostos de pirazinoisoquinolina
WO2010108103A1 (en) * 2009-03-19 2010-09-23 Concert Pharmaceuticals, Inc. Azepan-2-one derivatives
CA2759251C (en) 2009-04-23 2017-01-03 Concert Pharmaceuticals, Inc. 4-hydroxybutyric acid analogs
US8410082B2 (en) 2009-05-22 2013-04-02 Concert Pharmaceuticals, Inc. Fluorinated diaryl urea derivatives
EP2443089B1 (en) 2009-06-18 2014-03-05 Concert Pharmaceuticals Inc. Deuterated isoindoline-1,3-dione derivatives as pde4 and tnf-alpha inhibitors
US8501738B2 (en) 2009-06-23 2013-08-06 Concert Pharmaceuticals, Inc. Substituted triazolo-pyridazine derivatives
US8557815B2 (en) 2009-08-14 2013-10-15 Concert Pharmaceuticals, Inc. Substituted triazolophthalazine derivatives
JP2013503883A (ja) 2009-09-02 2013-02-04 コンサート ファーマシューティカルズ インコーポレイテッド 置換キサンチン誘導体
US9260432B2 (en) 2009-09-02 2016-02-16 Concert Pharmaceuticals, Inc. Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds
WO2011047315A1 (en) 2009-10-15 2011-04-21 Concert Pharmaceuticals, Inc. Subsitituted benzimidazoles
US8471034B2 (en) 2009-11-18 2013-06-25 Concert Pharmaceuticals, Inc. Niacin prodrugs and deuterated versions thereof
DE102010001040A1 (de) 2010-01-20 2011-07-21 Evonik RohMax Additives GmbH, 64293 (Meth)acrylat-Polymere zur Verbesserung des Viskositätsindexes
US8575361B2 (en) 2010-03-02 2013-11-05 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
EP3144296A1 (en) 2010-03-02 2017-03-22 Concert Pharmaceuticals, Inc. Deuterated tetrahydronaphthalene derivatives
US9226801B2 (en) * 2010-03-08 2016-01-05 Ibur, Llc Custom linkable imaging and multifunctional tray
WO2011116066A1 (en) 2010-03-17 2011-09-22 Concert Pharmaceuticals, Inc. Derivatives of dimethylcurcumin
WO2012009446A1 (en) 2010-07-16 2012-01-19 Concert Pharmaceuticals Inc. Novel pyrimidinecarboxamide derivatives
US9074233B2 (en) 2010-09-01 2015-07-07 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
WO2012031072A1 (en) 2010-09-01 2012-03-08 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
ES2804540T3 (es) 2011-02-14 2021-02-08 Concert Pharmaceuticals Inc Análogos deuterados de ácido 4–hidroxibutírico
US9145390B2 (en) 2011-03-03 2015-09-29 Concert Pharmaceuticals, Inc. Derivatives of pyrazole-substituted amino-heteroaryl compounds
WO2012122028A2 (en) 2011-03-04 2012-09-13 Concert Pharmaceuticals Inc. Pyrazinoisoquinoline compounds
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
IN2014DN08443A (es) 2012-04-13 2015-05-08 Concert Pharmaceuticals Inc
WO2013159026A1 (en) 2012-04-20 2013-10-24 Concert Pharmaceuticals, Inc. Deuterated rigosertib
US20150197525A1 (en) 2012-06-15 2015-07-16 Concert Pharmaceuticals, Inc. Deuterated derivatives of ruxolitinib
WO2014008417A1 (en) 2012-07-04 2014-01-09 Concert Pharmaceuticals, Inc. Deuterated vercirnon
CA2908929C (en) 2012-07-12 2021-01-26 Concert Pharmaceuticals, Inc. Deuterated idebenone
EP2882751B1 (en) 2012-07-30 2018-06-27 Concert Pharmaceuticals Inc. Deuterated ibrutinib
BR112015003153A2 (pt) 2012-08-17 2017-07-04 Concert Pharmaceuticals Inc baricitinib deuterado
JP2015534989A (ja) 2012-10-22 2015-12-07 コンサート ファーマシューティカルズ インコーポレイテッド {s−3−(4−アミノ−1−オキソ−イソインドリン−2−イル)(ピペリジン−3,4,4,5,5−d5)−2,6−ジオン}の固体形態
EP2943489B1 (en) 2013-01-09 2018-04-11 Concert Pharmaceuticals Inc. Deuterated momelotinib
CA2906396A1 (en) 2013-03-15 2014-09-25 Concert Pharmaceuticals Inc. Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
WO2015031741A1 (en) 2013-08-30 2015-03-05 Concert Pharmaceuticals, Inc. Deuterated derivatives of a thienotriazolodiazapine bromodomain-containing protein inhibitor
WO2015120393A1 (en) 2014-02-10 2015-08-13 Concert Pharmaceuticals, Inc. Substituted triazolobenzodiazepines
WO2016069630A1 (en) 2014-10-27 2016-05-06 Concert Pharmaceuticals, Inc. Pyrimidine phosphonic acid esters bearing at least one deuterium atom
WO2016160945A1 (en) 2015-03-31 2016-10-06 Concert Pharmaceuticals, Inc. Deuterated vx-661
WO2016176335A1 (en) 2015-04-27 2016-11-03 Concert Pharmaceuticals, Inc. Deuterated otx-015
MA42954A (fr) 2015-09-25 2018-08-01 Vertex Pharmaceuticals Europe Ltd Potentialisateurs cftr deutérés
WO2017087795A1 (en) 2015-11-19 2017-05-26 Concert Pharmaceuticals, Inc. Deuterated epi-743
WO2017143038A1 (en) 2016-02-16 2017-08-24 Concert Pharmaceuticals, Inc. Deuterated gft-505
CN111491629A (zh) 2017-11-22 2020-08-04 康塞特医药品公司 D-丝氨酸的氘化类似物及其用途
US11708331B2 (en) 2017-12-01 2023-07-25 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA002348B1 (ru) * 1995-02-22 2002-04-25 Новартис Аг Соединения 1-арил-2-ациламиноэтана и их применение в качестве антагонистов нейрокинина, в частности нейрокинина 1
MY132550A (en) 1996-08-22 2007-10-31 Novartis Ag Acylaminoalkenylene-amide derivatives as nk1 and nk2 antogonists
GB0010958D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
NO20084783L (no) 2008-11-12
US20090137797A1 (en) 2009-05-28
AU2007237482A1 (en) 2007-10-25
HK1125640A1 (en) 2009-08-14
US8008479B2 (en) 2011-08-30
ATE486853T1 (de) 2010-11-15
JO2630B1 (en) 2012-06-17
WO2007118651A1 (en) 2007-10-25
EP2010498A1 (en) 2009-01-07
AU2007237482B2 (en) 2011-03-17
GT200800209A (es) 2008-12-15
MY145069A (en) 2011-12-15
EP2010498B1 (en) 2010-11-03
SI2010498T1 (sl) 2011-03-31
TW200815358A (en) 2008-04-01
PL2010498T3 (pl) 2011-04-29
MA30394B1 (fr) 2009-05-04
DE602007010269D1 (de) 2010-12-16
PT2010498E (pt) 2011-02-08
KR20080108291A (ko) 2008-12-12
US20110282053A1 (en) 2011-11-17
RU2008145102A (ru) 2010-05-27
RU2433122C2 (ru) 2011-11-10
JP5208917B2 (ja) 2013-06-12
PE20071223A1 (es) 2008-01-22
NZ571142A (en) 2011-02-25
MX2008013117A (es) 2008-10-21
CA2645362A1 (en) 2007-10-25
CY1111294T1 (el) 2015-08-05
HRP20110045T1 (hr) 2011-02-28
CA2645362C (en) 2013-07-16
JP2009533369A (ja) 2009-09-17
ECSP088820A (es) 2008-11-27
CL2007001040A1 (es) 2008-03-14
DK2010498T3 (da) 2011-02-14

Similar Documents

Publication Publication Date Title
AR060506A1 (es) Compuestos organicos
PE20121047A1 (es) Derivados de tiazolilpiperidina como fungicidas
CY1119101T1 (el) Ναφθαλινο-ισοξαζολινες ως παραγοντες καταπολεμισης ασπονδυλων παρασιτων
BR112013009935B8 (pt) Compostos
PE20130375A1 (es) Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos
BR112012014858A2 (pt) agente antiplaqueta
PE20130155A1 (es) Derivados de ariletinilo
AR072166A1 (es) Derivado de piperidina y su uso como inhibidor de renina superior
AR078163A1 (es) Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes
CU20110052A7 (es) Compuestos orgánicos
PE20121159A1 (es) DERIVADOS DE PIRIDINA, PIRAZINA Y QUINOLINA COMO INHIBIDORES DE LA FOSFOINOSITIDA 3 CINASA Y LA mTOR
CO6362009A2 (es) Derivados de morfolinopurina
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
UY30045A1 (es) Derivados de pirimidina
PE20081362A1 (es) DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K
UY32606A (es) Sulfonamidas nematocidas
AR073130A1 (es) Derivados de 5-bencil-4-azolilmetil-4-espiro [2.4] heptanol, metodos para producir los mismos y agentes agrohorticolas y agentes para proteger material industrial que los contienen.
CO6220935A2 (es) Derivados de 1,2,4-triazol como moduladores de mglur5
AR079316A1 (es) Derivado de azol, compuestos intermedios para obtenerlo, metodos para producirlos y agente agro- horticola o agente de proteccion de material industrial que lo comprende
ES2567311T3 (es) 6-(3-Aza-biciclo[3.1.0]hex-3-il)-2-fenil-pirimidinas como antagonistas del receptor de ADP
AR080596A1 (es) Compuestos alquilamido y composiciones farmaceuticas
BR112013008675A2 (pt) métodos e composições para o tratamento de diabetes e dislipidemia
CR10780A (es) Inhibidores de cinasa
MA32192B1 (fr) Composés dérivés d'azétidines, leur préparation et leur application en thérapeutique
AR060962A1 (es) Proceso de preparacion de derivados de quinazolina e intermediarios de sintesis

Legal Events

Date Code Title Description
FA Abandonment or withdrawal